Combination therapy for advanced colorectal cancer with MSI-H/dMMR
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two medications, an immunotherapy (QL1706) and a blood-vessel-blocking drug (bevacizumab), for people with a type of colorectal cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have colorectal cancer that cannot be removed surgically or has spread to other parts of the body.
- Your tumor must have a specific genetic change called MSI-H or dMMR.
- You must not have received immunotherapy for this cancer before.
- You must be in reasonably good general health (able to do light activity, with adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) plus bevacizumab and chemotherapy as a first treatment for advanced colorectal cancer. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
Hear when a new Unresectable Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.